AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01448343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid management system 2000 (FMS)
Description: The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
Study NCT03272633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Receive IHC
Study NCT03522779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
Study NCT04433481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: T. Dabigatran 150 mg twice a day
Study NCT04433481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02961920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IE ratio 1:1
Description: Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
Study NCT02961920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IE ratio 1:2
Description: Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
Study NCT01169090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-0403
Description: SK-0403
Study NCT01169090 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01169090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin
Study NCT00568269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair
Description: Open repair is according to the Lichtenstein technique
Study NCT00568269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Description: The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
Study NCT00974493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.
Study NCT03272633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated Allogeneic Cells
Description: Correlative studies
Study NCT01996254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT01436058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol capsules
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine capsules
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cannabidiol
Description: Placebo cannabidiol capsules
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabidiol
Description: Placebo cannabidiol capsules
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: Placebo olanzapine capsules
Study NCT02088060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olanzapine
Description: Placebo olanzapine capsules
Study NCT01260220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential Antral Ablation
Description: The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
Study NCT01260220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental Antral ablation
Description: If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
Study NCT03018288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
Study NCT03018288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
Study NCT03018288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
Study NCT03018288 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Tissue for vaccine production and neo-epitope monitoring.
Study NCT03018288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Tissue for vaccine production and neo-epitope monitoring.
Study NCT03694249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Sodium
Description: Given by mouth
Study NCT03694249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by mouth
Study NCT02746497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally.
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short Acting Beta 2 Agonist
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Study NCT02889809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Short Acting Beta 2 Agonist
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Study NCT04107688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.
Study NCT04107688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
Study NCT01066897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Patients will received increasing dose of pramipexole
Study NCT03997409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
Study NCT03997409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
Study NCT03366233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental fatigue
Description: A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
Study NCT03366233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
Study NCT04463888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupational therapy
Description: occupational therapy targeted to goals that are relevant to the functional needs of the patient
Study NCT04463888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy
Description: occupational therapy targeted to goals that are relevant to the functional needs of the patient
Study NCT03875794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
Study NCT01763645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
Study NCT03534778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)
Description: LNY and LNR will be examined after neck dissection
Study NCT00599599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Oral Glucose Tolerance test (75g 2-hour)
Description: A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Modified Oral Glucose Tolerance Test (50g 4-hours)
Description: A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Matched isoglycemic clamp
Description: A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Hyperglycemic clamp with concurrent GLP-1 infusion
Description: An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Hyperglycemic Clamp with concurrent GIP infusion
Description: An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
Study NCT01975259 — intervention group
Intervention type: DRUG
Intervention: Hyperglycemic clamp with placebo infusion
Description: An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
Study NCT01975259 — intervention group
Intervention type: OTHER
Intervention: Liquid Meal Test (Carbohydrate-rich)
Description: A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
Study NCT01975259 — intervention group
Intervention type: OTHER
Intervention: Liquid Meal Test (Fat-rich)
Description: A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
Study NCT01975259 — intervention group
Intervention type: OTHER
Intervention: Liquid Meal Test (Mixed)
Description: A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
Study NCT01975259 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
Study NCT03754686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
Study NCT03754686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Best medical care and oral paracetamol twice daily for five days
Study NCT01132222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets